Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech to $195 from $160 and keeps a Buy rating on the shares. The company reported Q4 sales that meaningfully exceeded expectations and based on the 420 start forms received through mid-February, Vyjuvek is now on pace to surpass $300M in fiscal 2024 sales, the analyst tells investors in a research note. The firm accelerated its Vyjuvek ramp and revised peak sales projections upwards.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KRYS:
- New Sales & Marketing Risk for Krystal Biotech, Inc. – What’s the Latest?
- Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
- Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
- Krystal Biotech receives FDA Fast Track Designation for KB707
- Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
